News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Egetis presents Nomination Committee for the 2023 Annual General Meeting

October 25, 2022

Stockholm, Sweden, October 25, 2022. Egetis Therapeutics AB (publ) (NASDAQ Stockholm: EGTX) today announced the composition of the Nomination Committee for the 2023 Annual General Meeting (AGM) to be held on April 27, 2023, at 3.00 pm (CEST) in Stockholm, Sweden. The Nomination Committee is composed of members appointed by the three largest shareholders in terms of voting rights, that have accepted the invitation to join the Committee, based on the information received from Euroclear Sweden AB on 30 September 2022.

The Nomination Committee comprises the following members:
Cidro Förvaltning AB: Peter Lindell
Fjärde AP-fonden: Jan Särlvik
Avla Holding AB: Kennet Rooth
Thomas Lönngren, Chairman of the Board of Directors, will co-opt to the Nomination Committee.
In total, the Nomination Committee represents approximately 27.3 % of the total number of shares and votes in the Company. All representatives are independent in relation to the Company and its executive management.
The Committee's assignment is to present proposals regarding Chairman and other members of the Board, as well as remuneration to the Board´s members, to the AGM. The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals regarding the process to appoint the Nomination Committee for the AGM in 2024.
Shareholders who wish to submit proposals to the Nomination Committee can do so by email to (please label emails ‘Nomination Committee’). Proposals should be submitted no later than January 9, 2023.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10